Clinical Trial Search

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants

Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants

Primary: Number of Participants With Adverse Events (AEs) — 6 Participants

Primary: Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis — 100; 53.3; 46.7; 100 percentage of participants

Primary: Number of Participants Achieving a Complete Response — 51 Participants

Primary: Intervention Attendance (Feasibility) — 50 percentage of participants

Primary: Progression Free Survival (PFS) — 6.6; 7.5; 7.6 months

Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population) — 31; 34; 48 Percentage of Participants

Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657

Primary: The Number of Patients That Achieve Complete Response — 7 Participants

Primary: Therapeutic Efficacy — 1 Participants

Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants

Primary: Immune Response — 7 Particpants

Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…

Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…

Primary: Objective Response Rate — 6; 16; 11; 10 Participants

Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants

Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants

Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Overall Survival (OS): C1071003 Cohort A Versus TM-MM Database Using Inverse Probability of Treatment Weights (IPTW) Analysis — 13.27; 14.29 Months — p==0.615

Primary: Efficacy of BCMA CAR-T Cell Therapy — 25; 13 Participants — p=<0.0001

Primary: Response Rates by Blade Criteria — 2; 5; 3; 2 Participants

Primary: Event-free Survival — 29 percentage of participants

Primary: Safety Profile of Acalabrutinib With and Without Dexamethasone — 13; 14; 7; 7 Participants

Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002

Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859

Primary: Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant — 7; 6; 1; 12 participants

Primary: The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months — 17; 13 Participants